Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX – Research Report), Madrigal Pharmaceuticals (MDGL – Research Report) and Spyre Therapeutics (SYRE – Research Report).

GeoVax Labs (GOVX)

In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on GeoVax Labs, with a price target of $6.00. The company’s shares closed last Thursday at $2.56, close to its 52-week low of $2.04.

According to TipRanks.com, LeBoyer has 0 stars on 0-5 stars ranking scale with an average return of -10.3% and a 26.8% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Cadrenal Therapeutics, Inc., Unicycive Therapeutics, and Ocugen.

GeoVax Labs has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

See Insiders’ Hot Stocks on TipRanks >>

Madrigal Pharmaceuticals (MDGL)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Sell rating on Madrigal Pharmaceuticals, with a price target of $155.00. The company’s shares closed last Thursday at $236.20.

According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of -14.8% and a 29.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Checkpoint Therapeutics, and Scilex Holding Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $314.56 average price target.

Spyre Therapeutics (SYRE)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Spyre Therapeutics today and set a price target of $38.00. The company’s shares closed last Thursday at $27.44, close to its 52-week high of $28.66.

According to TipRanks.com, Slutsky is a 5-star analyst with an average return of 16.6% and a 50.0% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Olema Pharmaceuticals, and ALX Oncology Holdings.

Currently, the analyst consensus on Spyre Therapeutics is a Strong Buy with an average price target of $36.00, which is a 36.1% upside from current levels. In a report released today, Wells Fargo also upgraded the stock to Buy with a $35.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GOVX:

• GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
• Is GOVX a Buy, Before Earnings?
• GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
• GeoVax to Present at the 2024 BIO CEO & Investor Conference
• GeoVax Labs Avoids Nasdaq Delisting with Reverse Stock Split